Trial · NCT06899178
Atomoxetine in Melanocortin Obesity Syndrome
NCT06899178, Phase 2, Recruiting, Icahn School of Medicine at Mount Sinai
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Atomoxetine in Melanocortin Obesity Syndrome. Trials, record NCT06899178. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06899178
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Atomoxetine in Melanocortin Obesity Syndrome
- NCT number
- NCT06899178
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 20 participants, estimated
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Conditions
- Melanocortin Obesity Syndrome, MCOS
- Interventions
- Atomoxetine, Placebo
- First posted
- 2025-03-27
- Last updated
- 2026-08-07
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Body Mass Index (BMI) | 16 weeks | BMI will be calculated as kg/sq m. The sex appropriate CDC growth chart will be used to calculate BMI as a percent of the 95th percentile (BMI95). For patients \>20 years, the 20-year-old percentiles will be used. |
| Secondary | Resting Energy Expenditure (REE) | 16 weeks | Resting energy expenditure (REE) will be measured by indirect calorimetry after a minimum 1 hour of rest in the Clinical Research Center. Oxygen consumption and carbon dioxide production will be measured. The first 5-10 minutes of data will be discarded to allow participants to adjust to the metabolic cart. |
| Secondary | Healthy Eating Index (HEI) | 16 weeks | The VioScreen assessment provides a Healthy Eating Index (HEI) score to measure the quality of a person's diet. The HEI score ranges from 0 to 100, with higher scores indicating better eating habits. |
| Secondary | Hyperphagia Questionnaire (HQ) | 16 weeks | Hyperphagia will be assessed with the Hyperphagia Questionnaire (HQ) This is a 13-item questionnaire with each question answered on a 5-point scale. Two of the questions are qualitative. Full range is scored from 11 to 55. Higher score indicates greater hyperphagia. |
| Secondary | Hunger and Satiety Score | 16 weeks | Full range scored from 0 to 10 with higher score indicating greater hunger/satiety. |
| Secondary | Fasting Glucose Level | At week 0, week 16 and week 32. | A blood sugar test measures the amount of a sugar called glucose in a sample of blood. Fasting laboratory studies will be obtained at week 0, week 16 and week 32. |
| Secondary | Alanine Transaminase (ALT) Level | At week 0, week 16 and week 32. | The alanine transaminase (ALT) blood test measures the level of the enzyme ALT in the blood. ALT is an enzyme found in a high level in the liver. An enzyme is a protein that causes a specific chemical change in the body. Fasting laboratory studies will be obtained at week 0, week 16 and week 32. |
| Secondary | Fasting Insulin Level | At week 0, week 16 and week 32. | The insulin level in blood. Insulin is a hormone produced by beta cells in the pancreas. Fasting laboratory studies will be obtained at week 0, week 16 and week 32. |
| Secondary | Hemoglobin A1c | At week 0, week 16 and week 32. | A1C is a lab test that shows the average level of blood sugar (glucose) over the previous 3 months. It shows how well blood sugar is controlled to help prevent complications from diabetes. Fasting laboratory studies will be obtained at week 0, week 16 and week 32. |
| Secondary | Lipid Panel - Fasting LDL, HDL, Triglycerides | At week 0, week 16 and week 32. | A lipid profile is a blood test to measure different types of lipids: High-density lipoprotein cholesterol (HDL \[good\] cholesterol): HDL helps remove LDL from your blood. Low-density lipoprotein cholesterol (LDL \[bad\] cholesterol): LDL can build up in your blood vessels and increase your heart disease risk. Triglycerides: Your body makes some triglycerides. Triglycerides also come from the food you eat. Extra calories are turned into triglycerides and stored in fat cells for later use. Fasting laboratory studies will be obtained at week 0, week 16 and week 32. |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R01DK142434 | Targeting BDNF Using Atomoxetine for the Treatment of Obesity Caused by MC4R Insufficiency | HAN, JOAN CHRISTINE; SHOEMAKER, ASHLEY HALL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES | 2025 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06899178
GET https://conductscience.org/api/trials/v1/NCT06899178/registered